Latest rizatriptan benzoate Stories

WOODCLIFF LAKE, N.J., Jan. 2, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has begun shipping 5 mg and 10 mg strengths of rizatriptan benzoate tablets and 5 mg and 10 mg strengths of rizatriptan benzoate orally disintegrating tablets. Rizatriptan benzoate tablets and rizatriptan benzoate orally disintegrating tablets are each indicated for the acute treatment of migraine with or without aura in adults...

PITTSBURGH, Jan. 2, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg (base), and Rizatriptan Benzoate Tablets, 5 mg (base) and 10 mg (base). These products are the generic versions of Merck's Maxalt MLT® Tablets and Maxalt®...

BOCA RATON, Fla., Dec. 30, 2012 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Rizatriptan Benzoate Tablets. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA) for this product, which is being manufactured and supplied by Natco Pharma Limited, and will be available in both 5mg and 10mg strengths. Rizatriptan Benzoate Tablets are AB rated to Maxalt®, a $320 million dollar brand drug...